Dermatology Times

MARCH 24, 2025

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.

Eczema 41

Eczema Safety Treatments 41

The Dermatology Digest

JANUARY 24, 2024

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema, according to results from the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.

Eczema 36

Eczema Safety Office Treatments 36

Aesthetics Advisor

MARCH 10, 2024

Infants of mothers randomized to cut out eggs, milk, and fish were significantly less likely to have eczema even years later. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments. But what about diet?

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

SEPTEMBER 23, 2024

has given its official nod to delgocitinib (Anzupgo, Leo Pharma) cream for adults with moderate to severe chronic hand eczema (CHE). These trials evaluated the safety and efficacy of delgocitinib compared to cream vehicle. The European Commission (E.C.) In addition, the U.S. Both trials met their primary and all secondary endpoints.

Eczema 66

Eczema Safety Dermatology Clinic 66

The Dermatology Digest

DECEMBER 13, 2024

This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of nemolizumab in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 or older with moderate to severe atopic dermatitis.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

FEBRUARY 9, 2024

Brian Hilberdink, Leo Pharma’s EVP of North America, chatted with TDD about the significance of this study and the deleterious effect that chronic hand eczema can have on a person’s quality of life. Patients living with chronic hand eczema are impacted in their everyday lives and experience social, psychological, and physical effects.

Eczema 36

Eczema Marketing Dermatitis Safety 36

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. The post New Research Supports the Safety and Efficacy of Delgocitinib in CHE appeared first on The Dermatology Digest.

Safety 36

Safety Eczema Dermatology Treatments 36

The Dermatology Digest

JANUARY 21, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified.

Safety 36

Safety Eczema Social Media Dermatology 36

The Dermatology Digest

JANUARY 13, 2025

Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress. The REZOLVE-AD study enrolled patients with moderate-to-severe AD who had not previously received treatment with biologic or Janus kinase (JAK) inhibitor therapies.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

SEPTEMBER 26, 2024

The safety profile was consistent with that previously reported, the study showed. Safety is not an issue. At Week 56, IGA 0/1 was achieved in 47% and 49% and EASI-75 in 73% and 79% of patients with previous nemolizumab and nemolizumab-naïve patients, respectively. Improvements in itch, sleep, and QoL were also observed over time.

Dermatitis 74

Dermatitis Safety Management Eczema 74

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

MAY 16, 2024

This grant will fund a collaborative effort to investigate the safety, tolerability, efficacy, and durability of response of subcutaneous administration of dupilumab in pediatric patients with extensive alopecia areata, defined as affecting at least 30% of the scalp.

Eczema 69

Eczema Dermatitis Safety Clinic 69

The Dermatology Digest

FEBRUARY 14, 2024

The regulatory submissions of nemolizumab in prurigo nodularis are based on data from the phase III OLYMPIA clinical trial program, which evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in patients with prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. However, there are concerns about the safety of using retinol on younger skin due to the physiological differences between children’s and adults’ skin.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream also demonstrated highly statistically significant improvement in the proportion of patients with ≥75% improvement in the Eczema Area and Severity Index (EASI75) from baseline to Week 8 compared to patients on vehicle, a key secondary endpoint in the pivotal trials.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

DECEMBER 14, 2023

The National Eczema Association (NEA) announced the recipients for its 2023 research grants. The 2023 research grantees include: The Champion Research Grant encourages researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

Eczema 36

Eczema Dermatitis Hospital Networking 36

The Dermatology Digest

JANUARY 30, 2024

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, at the Oregon Health & Science University, in a news release.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

MARCH 7, 2024

The drug demonstrated significant and clinically relevant improvements in itch, patient-assessed quality-of-life indicators, inflammation, and safety, with minimal side effects and strong patient tolerability when compared to baseline.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Dermatology 36

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

DECEMBER 19, 2023

The primary endpoint of the clinical trial was safety and tolerability. Statistical significance was achieved for improvement in patient-reported eczema severity; the clinically relevant threshold of improvement by 4 or more points was met in six patients (75%).

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

JANUARY 23, 2024

The co-primary endpoints were Investigator’s Global Assessment (IGA) success (IGA score of 0/1 [clear/almost clear skin] with a reduction of ≥2 points from baseline at Week 16 and 75% improvement in the Eczema Area and Severity Index (EASI-75) at Week 16. Safety was assessed throughout the study.

Dermatitis 36

Dermatitis Safety Eczema Sustainability 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 10, 2024

No new safety signals were observed and there were no serious adverse events reported. Lilly plans to share full efficacy and safety results from the study at future congresses. Results at 16 weeks were consistent with the 16-week results from the ADhere and ADvocate 1 & 2 studies.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

Tricoci University

APRIL 19, 2024

Higher levels of stress are correlated to inflammation, which can manifest in acne, eczema, and psoriasis flare-ups. Currently, esthetic devices don’t need to verify their safety for Fitzpatrick Types 5 and 6. This year, people are interested in skincare that soothes the mind and enhances their mental state.

Esthetics 52

Esthetics Skincare Fitzpatrick Scale Aromatherapy 52

Aesthetics Advisor

JULY 21, 2024

The Council has urged manufacturers to enhance product safety measures, and advised consumers to exercise caution when selecting and using hair styling products. The Council urged suppliers to improve product labeling for consumer safety.

Waxing 36

Waxing Sensitive Skin Pores Eczema 36

The Dermatology Digest

MARCH 11, 2024

No new safety signals were observed in this trial. The Eczema Area and Severity Index (EASI)-75 score was also maintained in 76% of those receiving nemolizumab—both Q4W and Q8W—compared to 64% receiving a placebo.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

Kind of Stephen

AUGUST 3, 2022

Some dermatologists might recommend a patient with eczema to take a 5-to-10-minute bath in very dilute bleach (0.005%). It’s thought to help patients with eczema by reducing the levels of Staphylococcus aureus bacteria on the skin. Don’t mix acids or other cleaning chemicals into chlorine bleach, because you can make poisonous gases.

Sanitation and Sterilization 52

Sanitation and Sterilization Sanitation Eczema Skincare 52

The Dermatology Digest

MARCH 11, 2024

This could offer an important benefit in the treatment of AD patients.” These biomarker data suggest the modulation of inflammatory T cells via the blockade of OX40L and durable control of AD after amlitelimab withdrawal.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Dermatology Digest

OCTOBER 26, 2024

achieved an Eczema Area and Severity Index (EASI) of 75, 90, and 100, respectively. No new safety signals were observed after switching to upadacitinib from dupilumab without a washout period. In the switchers, 47.6% of patients escalated to upadacitinib 30mg in Period 2, and 52.4% were never dose escalated.

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36